XFOR

X4 Pharmaceuticals

Fundamental data last updated:April 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/07/26

Business Summary

X4 Pharmaceuticals operates as a clinical-stage biotechnology company focused on developing targeted therapies, generating value through intellectual property and eventual commercialization or partnering of approved drugs. Cash flow today is not driven by diversified product revenue but by capital markets funding and milestone-driven progress typical of biotech models. Its competitive moat, if realized, would stem from proprietary drug candidates, regulatory exclusivity, and specialized expertise in targeted therapeutic areas. The durability of that moat depends entirely on successful clinical outcomes, as failure in trials would materially impair asset value and eliminate its primary path to monetization.

 


Analyze XFOR on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$372

Forward P/E

-

PEG

-

PRICE TO SALES

4.9

PRICE TO BOOK

2

EV / EBITDA

-2.9

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$1.87

Next Year EPS Growth Estimate

-$0.96

Next Year Revenue Growth Estimate

-25.00%

Return on Equity (ROE)

-42.50%

FREE CASH FLOW

Operating Margin

-247.40%

Debt-to-Equity

0.4

Piotroski F-Score

3

Altman Z-Score

-0.6

Return on Invested Capital (ROIC)

-41.70%

Current Ratio

10.2

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze XFOR on TradingView

Gainseekers Quantitative Analysis

Summary

XFOR is a classic high-risk clinical-stage biotech priced at a $372M market cap with no earnings, negative EPS of -2.9, and no forward P/E to anchor valuation. The Altman Z-Score of -0.6 signals material financial distress risk, while ROIC at -41.70% and operating margins at -42.50% confirm a structurally cash-burning model. There is no traditional valuation support here—Price/Sales at 4.9 and Price/Book at 2 are being assigned to a company with negative returns and no profitability visibility. This is not a mispriced compounder; it is a speculative biotech binary where survival and pipeline execution matter more than multiples.

AI Exposure / Tech Reliance

As a Biotechnology company in Healthcare, XFOR operates in a sector increasingly influenced by AI-driven drug discovery and precision medicine. While no direct metrics are provided on R&D efficiency, the industry’s reliance on data analytics and computational biology means technological adaptability is essential for pipeline productivity. However, without profitability or capital efficiency, its ability to fully capitalize on AI tailwinds depends heavily on funding stability.

The Bull Case

A value-oriented biotech investor could argue that the balance sheet liquidity provides breathing room, with a Current Ratio of 10.2 indicating strong short-term solvency despite operating losses. Institutional Ownership at $11.67 suggests some professional participation, and a Consensus Rating of 3.90% paired with a Mean Target Price of 1.5 implies at least moderate analyst support. Price/Book at 2 is not excessive for a development-stage biotech with intellectual property assets, and improving EPS from -2.9 to an estimated -1.87 next year shows narrowing losses. For speculative GARP investors, the thesis rests on operational inflection: shrinking net losses, manageable near-term liquidity, and the asymmetric upside embedded in biotech pipelines.

The Bear Case

The bear case is far more concrete. Debt/Equity at -247.40% is a severe red flag, signaling a highly stressed capital structure relative to equity, while ROE at -25.00% and ROIC at -41.70% demonstrate systematic capital destruction. Operating Margin of -42.50% confirms that scale has not translated into efficiency, and with no P/E, no PEG, and negative earnings, investors lack any valuation framework tied to cash generation. The Altman Z-Score of -0.6 reinforces distress risk, meaning dilution or restructuring cannot be ruled out—this is fundamentally a cash-burning entity with fragile economics.

Market Sentiment & Smart Money

Short Interest %

3.90%

Analyst Consensus

1.5

Average Analyst Price Target

$11.67

Institutional Ownership %

90.30%

1-Year Beta

1.97

Insider Buying % (6 Mo)

0.60%%

Distance to 52-Week High

60.10%

Distance to 52-Week Low

303.70%

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.